Annual CFF
-$361.00 K
-$5.10 M-107.62%
December 1, 2023
Summary
- As of February 7, 2025, XRTX annual cash flow from financing activities is -$361.00 thousand, with the most recent change of -$5.10 million (-107.62%) on December 1, 2023.
- During the last 3 years, XRTX annual CFF has fallen by -$1.03 million (-153.82%).
- XRTX annual CFF is now -101.88% below its all-time high of $19.18 million, reached on December 31, 2021.
Performance
XRTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$22.20 K
-$13.30 K-149.44%
September 1, 2024
Summary
- As of February 7, 2025, XRTX quarterly cash flow from financing activities is -$22.20 thousand, with the most recent change of -$13.30 thousand (-149.44%) on September 1, 2024.
- Over the past year, XRTX quarterly CFF has increased by +$290.10 thousand (+92.89%).
- XRTX quarterly CFF is now -100.16% below its all-time high of $13.92 million, reached on December 1, 2021.
Performance
XRTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$1.36 M
-$5500.00-0.40%
September 1, 2024
Summary
- As of February 7, 2025, XRTX TTM cash flow from financing activities is $1.36 million, with the most recent change of -$5500.00 (-0.40%) on September 1, 2024.
- Over the past year, XRTX TTM CFF has increased by +$1.72 million (+476.68%).
- XRTX TTM CFF is now -92.98% below its all-time high of $19.37 million, reached on December 1, 2021.
Performance
XRTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
XRTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -107.6% | +92.9% | +476.7% |
| 3 y3 years | -153.8% | -0.9% | -71.0% |
| 5 y5 years | -125.8% | -0.9% | -71.0% |
XRTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -101.9% | at low | -100.2% | +95.2% | -93.0% | +476.7% |
| 5 y | 5-year | -101.9% | at low | -100.2% | +98.1% | -93.0% | +476.7% |
| alltime | all time | -101.9% | at low | -100.2% | +98.1% | -93.0% | +476.7% |
XORTX Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$22.20 K(+149.4%) | $1.36 M(-0.4%) |
| Jun 2024 | - | -$8900.00(-100.5%) | $1.37 M(+0.1%) |
| Mar 2024 | - | $1.70 M(-645.5%) | $1.36 M(-477.9%) |
| Dec 2023 | -$361.00 K(-107.6%) | -$312.30 K(+1770.1%) | -$361.10 K(-107.0%) |
| Sep 2023 | - | -$16.70 K(+65.3%) | $5.13 M(+9.5%) |
| Jun 2023 | - | -$10.10 K(-54.1%) | $4.68 M(-0.1%) |
| Mar 2023 | - | -$22.00 K(-100.4%) | $4.69 M(-0.5%) |
| Dec 2022 | $4.74 M(-75.3%) | $5.18 M(-1223.4%) | $4.71 M(-65.0%) |
| Sep 2022 | - | -$460.80 K(+7332.3%) | $13.45 M(-1.9%) |
| Jun 2022 | - | -$6200.00(<-9900.0%) | $13.71 M(-0.6%) |
| Mar 2022 | - | $0.00(-100.0%) | $13.79 M(-28.8%) |
| Dec 2021 | $19.18 M(+2759.5%) | - | - |
| Dec 2021 | - | $13.92 M(-6852.7%) | $19.37 M(+350.3%) |
| Sep 2021 | - | -$206.10 K(-351.0%) | $4.30 M(-5.3%) |
| Jun 2021 | - | $82.10 K(-98.5%) | $4.54 M(+0.4%) |
| Mar 2021 | - | $5.58 M(-583.7%) | $4.53 M(+574.9%) |
| Dec 2020 | $670.80 K(+1485.8%) | -$1.15 M(-3268.4%) | $670.90 K(-64.1%) |
| Sep 2020 | - | $36.40 K(-44.9%) | $1.87 M(+2.0%) |
| Jun 2020 | - | $66.10 K(-96.2%) | $1.83 M(+3.7%) |
| Mar 2020 | - | $1.72 M(+3970.2%) | $1.76 M(+4070.2%) |
| Dec 2019 | $42.30 K | $42.30 K(>+9900.0%) | $42.30 K(-155.7%) |
| Sep 2019 | - | $0.00(0.0%) | -$75.90 K(+52.1%) |
| Jun 2019 | - | $0.00(0.0%) | -$49.90 K(-34.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $0.00(-100.0%) | -$76.60 K(-105.5%) |
| Dec 2018 | $1.40 M(+1218.0%) | -$75.90 K(-391.9%) | $1.40 M(-6.1%) |
| Sep 2018 | - | $26.00 K(-197.4%) | $1.49 M(+1.8%) |
| Jun 2018 | - | -$26.70 K(-101.8%) | $1.47 M(-1.8%) |
| Mar 2018 | - | $1.48 M(+9432.9%) | $1.49 M(+7328.4%) |
| Dec 2017 | $106.30 K(-58.0%) | - | - |
| Nov 2017 | - | $15.50 K(>+9900.0%) | $20.10 K(-92.1%) |
| Aug 2017 | - | $0.00(0.0%) | $253.20 K(0.0%) |
| May 2017 | - | $0.00(0.0%) | $253.20 K(0.0%) |
| Mar 2017 | - | $0.00(-100.0%) | $253.20 K(0.0%) |
| Feb 2017 | $253.20 K(+195.8%) | $4600.00(-98.1%) | $253.20 K(+8.4%) |
| Dec 2016 | $85.60 K(-55.9%) | - | - |
| Nov 2016 | - | $248.60 K(>+9900.0%) | $233.50 K(+27.7%) |
| Aug 2016 | - | $0.00(0.0%) | $182.80 K(-1.8%) |
| May 2016 | - | $0.00(-100.0%) | $186.10 K(-4.1%) |
| Feb 2016 | $194.10 K(+77.7%) | -$15.10 K(-107.6%) | $194.10 K(-34.6%) |
| Nov 2015 | - | $197.90 K(+5897.0%) | $296.90 K(+203.3%) |
| Aug 2015 | - | $3300.00(-58.8%) | $97.90 K(+3.5%) |
| May 2015 | - | $8000.00(-90.9%) | $94.60 K(-13.4%) |
| Feb 2015 | $109.20 K | $87.70 K(-8072.7%) | $109.30 K(+406.0%) |
| Nov 2014 | - | -$1100.00(<-9900.0%) | $21.60 K(-4.8%) |
| Aug 2014 | - | $0.00(-100.0%) | $22.70 K(0.0%) |
| May 2014 | - | $22.70 K | $22.70 K |
FAQ
- What is XORTX Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for XORTX Therapeutics?
- What is XORTX Therapeutics annual CFF year-on-year change?
- What is XORTX Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for XORTX Therapeutics?
- What is XORTX Therapeutics quarterly CFF year-on-year change?
- What is XORTX Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for XORTX Therapeutics?
- What is XORTX Therapeutics TTM CFF year-on-year change?
What is XORTX Therapeutics annual cash flow from financing activities?
The current annual CFF of XRTX is -$361.00 K
What is the all time high annual CFF for XORTX Therapeutics?
XORTX Therapeutics all-time high annual cash flow from financing activities is $19.18 M
What is XORTX Therapeutics annual CFF year-on-year change?
Over the past year, XRTX annual cash flow from financing activities has changed by -$5.10 M (-107.62%)
What is XORTX Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of XRTX is -$22.20 K
What is the all time high quarterly CFF for XORTX Therapeutics?
XORTX Therapeutics all-time high quarterly cash flow from financing activities is $13.92 M
What is XORTX Therapeutics quarterly CFF year-on-year change?
Over the past year, XRTX quarterly cash flow from financing activities has changed by +$290.10 K (+92.89%)
What is XORTX Therapeutics TTM cash flow from financing activities?
The current TTM CFF of XRTX is $1.36 M
What is the all time high TTM CFF for XORTX Therapeutics?
XORTX Therapeutics all-time high TTM cash flow from financing activities is $19.37 M
What is XORTX Therapeutics TTM CFF year-on-year change?
Over the past year, XRTX TTM cash flow from financing activities has changed by +$1.72 M (+476.68%)